SALUTENSIN-DEMI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Salutensin-demi, and what generic alternatives are available?
Salutensin-demi is a drug marketed by Shire and is included in one NDA.
The generic ingredient in SALUTENSIN-DEMI is hydroflumethiazide; reserpine. There are two drug master file entries for this compound. Additional details are available on the hydroflumethiazide; reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SALUTENSIN-DEMI?
- What are the global sales for SALUTENSIN-DEMI?
- What is Average Wholesale Price for SALUTENSIN-DEMI?
Summary for SALUTENSIN-DEMI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| DailyMed Link: | SALUTENSIN-DEMI at DailyMed |
US Patents and Regulatory Information for SALUTENSIN-DEMI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire | SALUTENSIN-DEMI | hydroflumethiazide; reserpine | TABLET;ORAL | 012359-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
